Farallon Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-530,000	Closed	-$28.6M	–	168
2024 Q2	$28.6M	Buy	+530,000	New	+$30.7M	0.17%	66
2020 Q3	–	Sell	-150,000	Closed	-$11M	–	125
2020 Q2	$11M	Sell	150,000 -200,000	-57%	-$11.7M	0.09%	100
2020 Q1	$14.8M	Hold	350,000	–	–	0.14%	73
2019 Q4	$21.3M	Sell	350,000 -210,367	-38%	-$11.5M	0.16%	84
2019 Q3	$23M	Buy	560,367 +60,367	+12%	+$2.88M	0.19%	71
2019 Q2	$23.6M	Sell	500,000 -225,000	-31%	-$8.99M	0.16%	70
2019 Q1	$25.9M	Sell	725,000 -525,000	-42%	-$18.2M	0.21%	64
2018 Q4	$35.7M	Buy	1,250,000 +231,406	+23%	+$8.04M	0.31%	55
2018 Q3	$45.2M	Buy	1,018,594 +157,894	+18%	+$8.27M	0.32%	51
2018 Q2	$50.6M	Buy	860,700 +215,700	+33%	+$12.3M	0.37%	51
2018 Q1	$29.5M	Sell	645,000 -213,602	-25%	-$8.82M	0.25%	60
2017 Q4	$20.2M	Buy	+858,602	New	+$16.3M	0.2%	54